Mouse models of colorectal cancer as preclinical models

BioEssays

Volumn 37, Issue 8, 2015, Pages 909-920

  Mcintyre, Rebecca E ^a   Buczacki, Simon J A ^b   Arends, Mark J ^c   Adams, David J ^a  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Colorectal cancer; Disease biomarker; Mouse model; Ome and omics; Target identification; Target validation

Indexed keywords

BIOLOGICAL MARKER; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CELL LINE; CARCINOGENESIS; COLORECTAL CANCER; COLORECTAL CARCINOMA; COLORECTAL LIVER METASTASIS; EPIGENETICS; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC SCREENING; GENETICALLY ENGINEERED MOUSE STRAIN; GENOMICS; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATORY BOWEL DISEASE; MOUSE MODEL; NONHUMAN; STROMA CELL; TRANSCRIPTOMICS; TUMOR XENOGRAFT; ANIMAL; COLORECTAL NEOPLASMS; DRUG SCREENING; GENETICS; MOLECULARLY TARGETED THERAPY; NEOPLASMS, EXPERIMENTAL; SPECIES DIFFERENCE; TUMOR GENE;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; GENES, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS, EXPERIMENTAL; SPECIES SPECIFICITY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937519777     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201500032     Document Type: Article

References (115)

1. Torre LA, Bray F, Siegel RL, Ferlay J, et al. 2015. Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108.
2. TCGA. 2012. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-7.
3. Fearon ER. 2011. Molecular genetics of colorectal cancer. Annu Rev Pathol 6: 479-507.
4. Sjoblom T, Jones S, Wood LD, Parsons DW, et al. 2006. The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-74.
5. Albuquerque C, Breukel C, van der Luijt R, Fidalgo P, et al. 2002. The "just-right" signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade. Hum Mol Genet 11: 1549-60.
6. March HN, Rust AG, Wright NA, ten Hoeve J, et al. 2011. Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. Nat Genet 43: 1202-9.
7. Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, et al. 2012. Recurrent R-spondin fusions in colon cancer. Nature 488: 660-4.
8. Van der Flier LG, Clevers H. 2009. Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu Rev Physiol 71: 241-60.
9. Lau T, Chan E, Callow M, Waaler J, et al. 2013. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res 73: 3132-44.
10. Walther A, Johnstone E, Swanton C, Midgley R, et al. 2009. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 9: 489-99.
11. Brannon AR, Vakiani E, Sylvester BE, Scott SN, et al. 2014. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol 15: 454.
12. Jones S, Chen W-D, Parmigiani G, Diehl F, et al. 2008. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci USA 105: 4283-8.
13. Van Cutsem E, Nordlinger B, Cervantes A. 2010. Advanced colorectal cancer: ESMO clinical practice guidelines for treatment. Ann Oncol Off J Eur Soc Med Oncol ESMO 21: v93-v97.
14. Jemal A, Bray F, Center MM, Ferlay J, et al. 2011. Global cancer statistics. CA Cancer J Clin 61: 69-90.
15. Garraway LA, Janne PA. 2012. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov 2: 214-26.
16. Montagut C, Dalmases A, Bellosillo B, Crespo M, et al. 2012. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat Med 18: 221-3.
17. Valtorta E, Misale S, Sartore-Bianchi A, Nagtegaal ID, et al. 2013. KRAS gene amplification in colorectal cancer and impact on response to. Int J Cancer J Int Cancer 133: 1259-65.
18. Sharpless NE, Depinho RA. 2006. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 5: 741-54.
19. Voskoglou-Nomikos T, Pater JL, Seymour L. 2003. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res Off J Am Assoc Cancer Res 9: 4227-39.
20. Ernst M, Ramsay RG. 2012. Colorectal cancer mouse models: integrating inflammation and the stroma. J Gastroenterol Hepatol 27: 39-50.
21. Fidler IJ. 2003. The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nat Rev Cancer 3: 453-8.
22. Medema JP, Vermeulen L. 2011. Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. Nature 474: 318-26.
23. Huh D, Hamilton GA, Ingber DE. 2011. From 3D cell culture to organs-on-chips. Trends Cell Biol 21: 745-54.
24. Jorgensen C, Sherman A, Chen GI, Pasculescu A, et al. 2009. Cell-specific information processing in segregating populations of Eph receptor ephrin-expressing cells. Science 326: 1502-9.
25. Sato T, Vries RG, Snippert HJ, van de Wetering M, et al. 2009. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459: 262-5.
26. Bedard PL, Hansen AR, Ratain MJ, Siu LL. 2013. Tumour heterogeneity in the clinic. Nature 501: 355-64.
27. Flatmark K, Maelandsmo GM, Martinsen M, Rasmussen H, et al. 1990. 2004. Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic capacities in an orthotopic model in nude mice. Eur J Cancer Oxf Engl 40: 1593-8.
28. Rosenbluh J, Nijhawan D, Cox AG, Li X, et al. 2012. β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 151: 1457-73.
29. Vermeulen L, De Sousa Melo EF, van der Heijden M, Cameron K, et al. 2010. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 12: 468-76.
30. Pocard M, Tsukui H, Salmon RJ, Dutrillaux B, et al. 1996. Efficiency of orthotopic xenograft models for human colon cancers. Vivo Athens Greece 10: 463-9.
31. Hackl C, Man S, Francia G, Milsom C, et al. 2013. Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut 62: 259-71.
32. Lavilla-Alonso S, Abo-Ramadan U, Halavaara J, Escutenaire S, et al. 2011. Optimized mouse model for the imaging of tumor metastasis upon experimental therapy. PLoS ONE 6: e26810.
33. Jin H, Yang Z, Wang J, Zhang S, et al. 2011. A superficial colon tumor model involving subcutaneous colon translocation and orthotopic transplantation of green fluorescent protein-expressing human colon tumor. Tumour Biol J Int Soc Oncodevelopmental Biol Med 32: 391-7.
34. Cespedes MV, Espina C, Garcia-Cabezas MA, Trias M, et al. 2007. Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites. Am J Pathol 170: 1077-85.
35. Fu XY, Besterman JM, Monosov A, Hoffman RM. 1991. Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc Natl Acad Sci USA 88: 9345-9.
36. Rashidi B, Gamagami R, Sasson A, Sun FX, et al. 2000. An orthotopic mouse model of remetastasis of human colon cancer liver metastasis. Clin Cancer Res Off J Am Assoc Cancer Res 6: 2556-61.
37. Garralda E, Paz K, Lopez-Casas PP, Jones S, et al. 2014. Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment. Clin Cancer Res Off J Am Assoc Cancer Res 20: 2476-84.
38. Hylander BL, Punt N, Tang H, Hillman J, et al. 2013. Origin of the vasculature supporting growth of primary patient tumor xenografts. J Transl Med 11: 110.
39. Julien S, Merino-Trigo A, Lacroix L, Pocard M, et al. 2012. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res Off J Am Assoc Cancer Res 18: 5314-28.
40. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, et al. 2006. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-4.
41. Kim B-G, Li C, Qiao W, Mamura M, et al. 2006. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature 441: 1015-9.
42. Waterston RH, Lindblad-Toh K, Birney E, Rogers J, et al. 2002. Initial sequencing and comparative analysis of the mouse genome. Nature 420: 520-62.
43. Frese KK, Tuveson DA. 2007. Maximizing mouse cancer models. Nat Rev Cancer 7: 645-58.
44. Francis JC, Melchor L, Campbell J, Kendrick H, et al. 2015. Whole-exome DNA sequence analysis of Brca2- and Trp53-deficient mouse mammary gland tumours. J Pathol 236: 186-200.
45. McIntyre RE, van der Weyden L, Adams DJ. 2012. Cancer gene discovery in the mouse. Curr Opin Genet Dev 22: 14-20.
46. Nguyen TLA, Vieira-Silva S, Liston A, Raes J. 2015. How informative is the mouse for human gut microbiota research? Dis Model Mech 8: 1-16.
47. Moser AR, Pitot HC, Dove WF. 1990. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247: 322-4.
48. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, et al. 1992. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256: 668-70.
49. Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, et al. 1991. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253: 665-9.
50. Huang J, Papadopoulos N, McKinley AJ, Farrington SM, et al. 1996. APC mutations in colorectal tumors with mismatch repair deficiency. Proc Natl Acad Sci USA 93: 9049-54.
51. Prolla TA, Baker SM, Harris AC, Tsao JL, et al. 1998. Tumour susceptibility and spontaneous mutation in mice deficient in Mlh1, Pms1 and Pms2 DNA mismatch repair. Nat Genet 18: 276-9.
52. Wheeler JM, Bodmer WF, Mortensen NJ. 2000. DNA mismatch repair genes and colorectal cancer. Gut 47: 148-53.
53. Kane MF, Loda M, Gaida GM, Lipman J, et al. 1997. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 57: 808-11.
54. Reitmair AH, Schmits R, Ewel A, Bapat B, et al. 1995. MSH2 deficient mice are viable and susceptible to lymphoid tumours. Nat Genet 11: 64-70.
55. Kucherlapati MH, Lee K, Nguyen AA, Clark AB, et al. 2010. An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents. Gastroenterology 138: 993-1002.
56. Chen X, Halberg RB, Burch RP, Dove WF. 2008. Intestinal adenomagenesis involves core molecular signatures of the epithelial-mesenchymal transition. J Mol Histol 39: 283-94.
57. Halberg RB, Waggoner J, Rasmussen K, White A, et al. 2009. Long-lived Min mice develop advanced intestinal cancers through a genetically conservative pathway. Cancer Res 69: 5768-75.
58. Zeineldin M, Neufeld KL. 2013. More than two decades of Apc modeling in rodents. Biochim Biophys Acta 1836: 80-89.
59. Sansom OJ, Reed KR, Hayes AJ, Ireland H, et al. 2004. Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev 18: 1385-90.
60. Barker N, Ridgway RA, van Es JH, van de Wetering M, et al. 2009. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457: 608-11.
61. Roper J, Hung KE. 2012. Priceless GEMMs: genetically engineered mouse models for colorectal cancer drug development. Trends Pharmacol Sci 33: 449-55.
62. Hung KE, Maricevich MA, Richard LG, Chen WY, et al. 2010. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc Natl Acad Sci USA 107: 1565-70.
63. Buchert M, Athineos D, Abud HE, Burke ZD, et al. 2010. Genetic dissection of differential signaling threshold requirements for the Wnt/beta-catenin pathway in vivo. PLoS Genet 6: e1000816.
64. Shibata H, Toyama K, Shioya H, Ito M, et al. 1997. Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science 278: 120-3.
65. Leedham SJ, Graham TA, Oukrif D, McDonald SAC, et al. 2009. Clonality, founder mutations, and field cancerization in human ulcerative colitis-associated neoplasia. Gastroenterology 132: 542-50.
66. Van der Sluis M, De Koning BAE, De Bruijn ACJM, Velcich A, et al. 2006. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 131: 117-29.
67. Sohn KJ, Shah SA, Reid S, Choi M, et al. 2001. Molecular genetics of ulcerative colitis-associated colon cancer in the interleukin 2- and beta(2)-microglobulin-deficient mouse. Cancer Res 61: 6912-17.
68. Cooper HS, Murthy S, Kido K, Yoshitake H, et al. 2000. Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology. Carcinogenesis 21: 757-68.
69. Neufert C, Becker C, Neurath MF. 2007. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc 2: 1998-2004.
70. Kandoth C, McLellan MD, Vandin F, Ye K, et al. 2013. Mutational landscape and significance across 12 major cancer types. Nature 502: 333-9.
71. Starr TK, Allaei R, Silverstein KAT, Staggs RA, et al. 2009. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science 323: 1747-50.
72. Starr TK, Scott PM, Marsh BM, Zhao L, et al. 2011. A Sleeping Beauty transposon-mediated screen identifies murine susceptibility genes for adenomatous polyposis coli (Apc)-dependent intestinal tumorigenesis. Proc Natl Acad Sci USA 108: 5765-70.
73. Forbes SA, Bindal N, Bamford S, Cole C, et al. 2011. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39: D945-50.
74. Zhang F, Yu X. 2011. WAC, a functional partner of RNF20/40, regulates histone H2B ubiquitination and gene transcription. Mol Cell 41: 384-97.
75. Kale VP, Amin SG, Pandey MK. 2015. Targeting ion channels for cancer therapy by repurposing the approved drugs. Biochim Biophys Acta in press. DOI: 10.1016/j.bbamem.2015.03.034
76. Than BLN, Goos JACM, Sarver AL, O'sullivan MG, et al. 2014. The role of KCNQ1 in mouse and human gastrointestinal cancers. Oncogene 33: 3861-68.
77. Chen X, Halberg RB, Ehrhardt WM, Torrealba J, et al. 2003. Clusterin as a biomarker in murine and human intestinal neoplasia. Proc Natl Acad Sci USA 100: 9530-5.
78. Merlos-Suarez A, Barriga FM, Jung P, Iglesias M, et al. 2011. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 8: 511-24.
79. Zoubeidi A, Chi K, Gleave M. 2010. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res Off J Am Assoc Cancer Res 16: 1088-93.
80. Hung KE, Faca V, Song K, Sarracino DA, et al. 2009. Comprehensive proteome analysis of an Apc mouse model uncovers proteins associated with intestinal tumorigenesis. Cancer Prev Res Phila Pa 2: 224-33.
81. Talieri M, Papadopoulou S, Scorilas A, Xynopoulos D, et al. 2004. Cathepsin B and cathepsin D expression in the progression of colorectal adenoma to carcinoma. Cancer Lett 205: 97-106.
82. Fijneman RJA, de Wit M, Pourghiasian M, Piersma SR, et al. 2012. Proximal fluid proteome profiling of mouse colon tumors reveals biomarkers for early diagnosis of human colorectal cancer. Clin Cancer Res Off J Am Assoc Cancer Res 18: 2613-24.
83. Campo E, Munoz J, Miquel R, Palacin A, et al. 1994. Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. Am J Pathol 145: 301-9.
84. Grimm C, Chavez L, Vilardell M, Farrall AL, et al. 2013. DNA-methylome analysis of mouse intestinal adenoma identifies a tumour-specific signature that is partly conserved in human colon cancer. PLoS Genet 9: e1003250.
85. De Sousa EMF, Vermeulen L, Richel D, Medema JP. 2011. Targeting Wnt signaling in colon cancer stem cells. Clin Cancer Res Off J Am Assoc Cancer Res 17: 647-53.
86. Huang S-MA, Mishina YM, Liu S, Cheung A, et al. 2009. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461: 614-20.
87. He TC, Sparks AB, Rago C, Hermeking H, et al. 1998. Identification of c-MYC as a target of the APC pathway. Science 281: 1509-12.
88. Van de Wetering M, Sancho E, Verweij C, de Lau W, et al. 2002. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111: 241-50.
89. Bettess MD, Dubois N, Murphy MJ, Dubey C, et al. 2005. C-Myc is required for the formation of intestinal crypts but dispensable for homeostasis of the adult intestinal epithelium. Mol Cell Biol 25: 7868-78.
90. Sansom OJ, Meniel VS, Muncan V, Phesse TJ, et al. 2007. Myc deletion rescues Apc deficiency in the small intestine. Nature 446: 676-9.
91. Sur IK, Hallikas O, Vaharautio A, Yan J, et al. 2012. Mice lacking a Myc enhancer that includes human SNP rs6983267 are resistant to intestinal tumors. Science 338: 1360-3.
92. Delmore JE, Issa GC, Lemieux ME, Rahl PB, et al. 2011. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146: 904-17.
93. Massague J. 2012. TGFbeta signalling in context. Nat Rev Mol Cell Biol 13: 616-30.
94. Calon A, Espinet E, Palomo-Ponce S, Tauriello DVF, et al. 2012. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell 22: 571-84.
95. Zubeldia IG, Bleau A-M, Redrado M, Serrano D, et al. 2013. Epithelial to mesenchymal transition and cancer stem cell phenotypes leading to liver metastasis are abrogated by the novel TGFbeta1-targeting peptides P17 and P 144. Exp Cell Res 319: 12-22.
96. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, et al. 2013. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39: 782-95.
97. Santarelli RL, Pierre F, Corpet DE. 2008. Processed meat and colorectal cancer: a review of epidemiologic and experimental evidence. Nutr Cancer 60: 131-44.
98. Tjalsma H, Boleij A, Marchesi JR, Dutilh BE. 2012. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol 10: 575-82.
99. Crosara Teixeira M, Braghiroli MI, Sabbaga J, Hoff PM. 2014. Primary prevention of colorectal cancer: myth or reality? World J Gastroenterol WJG 20: 15060-9.
100. Kinzler KW, Vogelstein B. 1996. Lessons from hereditary colorectal cancer. Cell 87: 159-70.
101. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, et al. 1994. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 106: 42-48.
102. Bos JL. 1989. Ras oncogenes in human cancer: a review. Cancer Res 49: 4682-9.
103. King B, Trimarchi T, Reavie L, Xu L, et al. 2013. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell 153: 1552-66.
104. Iwatsuki M, Mimori K, Ishii H, Yokobori T, et al. 2010. Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: clinical significance. Int J Cancer J Int Cancer 126: 1828-37.
105. Markowitz S, Wang J, Myeroff L, Parsons R, et al. 1995. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268: 1336-8.
106. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, et al. 2012. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483: 570-5.
107. Klijn C, Durinck S, Stawiski EW, Haverty PM, et al. 2015. A comprehensive transcriptional portrait of human cancer cell lines. Nat Biotechnol 33: 306-12.
108. Chen S, Sanjana NE, Zheng K, Shalem O, et al. 2015. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell 160: 1246-60.
109. Robanus-Maandag EC, Koelink PJ, Breukel C, Salvatori DCF, et al. 2010. A new conditional Apc-mutant mouse model for colorectal cancer. Carcinogenesis 31: 946-52.
110. Clarke AR, Cummings MC, Harrison DJ. 1995. Interaction between murine germline mutations in p53 and APC predisposes to pancreatic neoplasia but not to increased intestinal malignancy. Oncogene 11: 1913-20.
111. Haigis KM, Kendall KR, Wang Y, Cheung A, et al. 2008. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 40: 600-8.
112. Hamamoto T, Beppu H, Okada H, Kawabata M, et al. 2002. Compound disruption of smad2 accelerates malignant progression of intestinal tumors in apc knockout mice. Cancer Res 62: 5955-61.
113. Munoz NM, Upton M, Rojas A, Washington MK, et al. 2006. Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation. Cancer Res 66: 9837-44.
114. Takaku K, Oshima M, Miyoshi H, Matsui M, et al. 1998. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 92: 645-56.
115. Babaei-Jadidi R, Li N, Saadeddin A, Spencer-Dene B, et al. 2011. FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation. J Exp Med 208: 295-312.